Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)

Abstract

Dalbavancin and comparators were susceptibility tested against 8643 Gram-positive bacteria from 74 hospitals located in Europe and the United States by broth microdilution method. The most common organisms were Staphylococcus aureus (45.2%), Enterococcus faecalis (12.2%), and Staphylococcus epidermidis (8.9%), but rank order varied markedly by geographic region. Dalbavancin demonstrated potent activity and broad spectrum, with MIC₉₀ values of 0.03 mg/L for Staphylococcus aureus, β-haemolytic streptococci, and viridans group streptococci; 0.06 mg/L for Enterococcus faecalis and Staphylococcus epidermidis; and 0.12 mg/L for vancomycin-susceptible Enterococcus faecium. All organisms, except vancomycin-resistant enterococci and 1 Staphylococcus haemolyticus isolate, were inhibited at ≤ 0.25 mg/L of dalbavancin.

Introduction

Bloodstream infection (BSI) includes a wide variety of syndromes caused by a range of pathogens; accordingly, BSI produces significant patient morbidity and mortality worldwide [1]. Changing pathogen distribution, antimicrobial resistance rates, and demographics may affect the epidemiology of BSI. Thus, it is important to continuously monitor trends in the pathogen frequency and antimicrobial resistance patterns of organisms causing BSI globally [2, 3]. Examining microbiological trends can help when planning diagnostic approaches, treatment strategies, and prevention programs.

The International Dalbavancin Evaluation of Activity (IDEA) Program monitors the in vitro activity of dalbavancin and comparators against Gram-positive bacteria causing BSI and other infections in Europe (EU) and the United States (US). Strengths of this surveillance program include the broad geographic distribution of medical centers submitting clinical isolates and the use of reference identification and antimicrobial susceptibility testing methods at a central laboratory [4].

Dalbavancin belongs to the lipoglycopeptide class of antimicrobial agents that act by interrupting bacterial cell wall synthesis resulting in bacterial death [5]. Dalbavancin allows for convenient parenteral administration to treat acute bacterial skin and skin structure infections, either through a single dose of 1500 mg or one dose of 1000 mg followed by another dose of 500 mg a week later [6, 7]. Dalbavancin was approved in the US (2014) and EU (2015) to treat adults with acute bacterial skin and skin structure infection (ABSSSI) caused by Staphylococcus aureus, including methicillin-resistant (MRSA) isolates, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group, and vancomycin-susceptible Enterococcus faecalis. Dalbavancin is not licensed to treat patients with BSI, but it could be an important option to treat infections due to highly resistant Gram-positive cocci [8, 9]. It is also important to note that ABSSSI can be secondarily complicated by bacteremia or it can be the result of skin/subcutaneous tissue seeding during bacteremia from a distant focus. Furthermore, catheter-related infections may commonly present as both ABSSSI and BSI due to the same organism. In this investigation, we evaluated dalbavancin in vitro activity and potency when tested against a large collection of Gram-positive bacteria collected from patients with BSI in US and European medical centers.

Materials and methods

Organism collection

A total of 8643 organisms were consecutively collected (1/patient) from 74 medical centers located in western Europe (W-EU; n = 3330; 28 centers from 10 countries: Belgium, France, Germany, Ireland, Italy, Portugal, Spain, Sweden, Switzerland, and the UK), eastern Europe (E-EU; n = 769; 13 centers from 10 countries: Belarus, Czech Republic, Greece, Hungary, Israel, Poland, Romania, Russia, Slovenia, and Turkey), and the US (n = 4544; 33 centers). Isolates determined to be clinically significant based on local guidelines were submitted to a central monitoring laboratory (JMI Laboratories, North Liberty, IA, USA) [2]. Species identification was initially performed by the participating laboratories then confirmed at JMI Laboratories by standard algorithms and/or MALDI-TOF.

Antimicrobial susceptibility testing

Isolates were susceptibility tested by broth microdilution following guidelines in the CLSI M07 document [10] with reference 96-well panels manufactured by JMI Laboratories. All isolates were tested at JMI Laboratories. Polysorbate-80 at a final concentration of 0.002% was added to the medium to test dalbavancin. Isolates with elevated dalbavancin MIC values (> 0.25 mg/L) were retested to confirm the dalbavancin MIC results. Quality assurance was performed by concurrently testing the following CLSI-recommended quality control (QC) reference strains: S. aureus ATCC 29213, E. faecalis ATCC 29212, and S. pneumoniae ATCC 49619. All QC results were within published acceptable ranges. Dalbavancin breakpoints approved by the US FDA (≤ 0.25 mg/L) [6], CLSI (≤ 0.25 mg/L) [11], and EUCAST (≤ 0.125 mg/L) [12] were applied when appropriate. US FDA, CLSI, and EUCAST breakpoint criteria were used for the comparator agents.

Results

Overall, the most common Gram-positive organisms were S. aureus, E. faecalis, S. epidermidis, β-hemolytic streptococci (BHS), and E. faecium, but rank order varied markedly by geographic region (Fig. 1). S. aureus ranked first in all 3 regions, with frequencies varying from 49.2% in the US to 40.3% in W-EU. The second most common organism was E. faecalis in the US and W-EU and S. pneumoniae in E-EU. The third most frequently isolated Gram-positive organism was BHS in the US and E-EU and E. faecium in W-EU (Fig. 1).

Fig. 1.

Frequency of Gram-positive bacteria isolated from patients hospitalized with bacteremia in the United States (US), western Europe (W-EU), and eastern Europe (E-EU) in 2018–2020

Dalbavancin was highly active against methicillin-susceptible S. aureus (MSSA) and MRSA, with an MIC₉₀ of 0.03 mg/L in all 3 regions and 100.0% susceptibility overall per US FDA, CLSI, and EUCAST criteria (Tables 1 and 2). Based on MIC_50/90 values, dalbavancin (MIC_50/90, 0.03/0.03 mg/L) was 8- to 16-fold more active than daptomycin (MIC_50/90, 0.25/0.5 mg/L) and 32-fold more active than vancomycin (MIC_50/90, 1/1 mg/L) against S. aureus (Table 2). MRSA rates were higher in the US (41.3%) than W-EU (21.5%) or E-EU (27.3%). S. aureus susceptibility to ceftaroline ranged from 96.6% (US) to 95.4% (W-EU), whereas S. aureus susceptibility to clindamycin and levofloxacin (US FDA and CLSI criteria) was lower in the US (85.5% and 67.6%, respectively) than W-EU (96.2% and 79.4%, respectively) and E-EU (89.1% and 85.8%, respectively; Table 2).

Table 1.

Antimicrobial activity of dalbavancin tested against the most common organisms and organism groups

Organism (no. of isolates)	No. and cumulative % of isolates inhibited at dalbavancin MIC (mg/L) of:
	≤ 0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	> 2	MIC50	MIC90
S. aureus (3908)	4 0.1	31 0.9	970 25.7	2,840 98.4	62  > 99.9	1 100.0						0.03	0.03
MSSA (2607)	3 0.1	25 1.1	661 26.4	1882 98.6	35  > 99.9	1 100.0						0.03	0.03
MRSA (1301)	1 0.1	6 0.5	309 24.3	958 97.9	27 100.0							0.03	0.03
E. faecalis (1053)			159 15.1	752 86.5	117 97.6	6 98.2	1 98.3	0 98.3	0 98.3	1 98.4	17 100.0	0.03	0.06
VAN-S (≤ 4 mg/L) (1030)			159 15.4	752 88.4	112 99.3	6 99.9	1 100.0					0.03	0.06
S. epidermidis (765)	3 0.4	17 2.6	201 28.9	436 85.9	90 97.6	17 99.9	1 100.0					0.03	0.06
β-hemolytic streptococci (735)	130 17.7	213 46.7	307 88.4	66 97.4	17 99.7	2 100.0						0.015	0.03
E. faecium (659)			71 10.8	155 34.3	138 55.2	52 63.1	15 65.4	6 66.3	3 66.8	11 68.4	208 100.0	0.06	> 2
VAN-S (≤ 4 mg/L) (397)			68 17.1	143 53.1	133 86.6	47 98.5	6 100.0					0.03	0.12
Viridans group streptococci (508)	116 22.8	126 47.6	140 75.2	100 94.9	20 98.8	6 100.0						0.015	0.03
S. pneumoniae (461)	12 2.6	245 55.7	187 96.3	16 99.8	1 100.0							0.008	0.015
S. hominis (175)	1 0.6	4 2.9	52 32.6	95 86.9	19 97.7	4 100.0						0.03	0.06
S. haemolyticus (104)			3 2.9	16 18.3	51 67.3	29 95.2	4 99.0	1 100.0				0.06	0.12

Abbreviations: VAN-S, vancomycin-susceptible

Table 2.

Antimicrobial activity of dalbavancin and comparator agents against the most common Gram-positive cocci isolated from patients with BSI in the United States (US), western Europe (W-EU), and eastern Europe (E-EU)

Organism/antimicrobial (no. tested)	MIC50 a	MIC90 a	% Susceptible per US FDA and CLSI (no. tested)
			US	W-EU	E-EU
S. aureus (3908)			(2,235)	(1,343)	(330)
Dalbavancin	0.03	0.03	100.0	100.0	100.0
Daptomycin	0.25	0.5	> 99.9	100.0	100.0
Vancomycin	1	1	100.0	100.0	100.0
Teicoplanin	0.5	0.5	100.0	100.0	100.0
Linezolid	1	2	100.0	100.0	100.0
Oxacillin	0.5	> 2	58.7	78.5	72.7
Ceftaroline	0.25	1	96.6	95.4	96.4
Clindamycin	0.06	> 2	85.5	96.2	89.1
Levofloxacin	0.25	> 4	67.6	79.4	85.8
Tetracycline	≤ 0.5	≤ 0.5	95.1	96.0	83.6
TMP-SMXb	≤ 0.5	≤ 0.5	97.7	99.8	99.7
E. faecalis (1053)			(515)	(463)	(75)
Dalbavancin	0.03	0.06	97.9 c	98.7 c	98.7 c
Daptomycin	1	1	99.2	99.6	100.0
Vancomycin	1	2	97.5	98.3	97.3
Teicoplanin	0.5	0.5	97.9	98.7	98.7
Linezolid	1	2	99.8	99.8	97.3
Ampicillin	1	1	100.0	100.0	100.0
Levofloxacin	1	> 4	78.8	73.4	70.7
S. epidermidis (765)			(396)	(332)	(37)
Dalbavancin	0.03	0.06	[100.0]d	[100.0]d	[100.0]d
Daptomycin	0.25	0.5	100.0	100.0	100.0
Vancomycin	2	2	100.0	100.0	100.0
Teicoplanin	2	8	99.2	99.4	97.3
Linezolid	1	1	93.9	96.4	94.6
Oxacillin	> 2	> 2	26.8	33.1	13.5
Clindamycin	0.06	> 2	52.5	66.6	70.3
Levofloxacin	4	> 4	40.9	44.6	24.3
Tetracycline	1	> 8	80.8	85.2	73.0
TMP-SMXb	1	8	54.3	58.4	73.0
β-hemolytic streptococci (735)			(430)	(228)	(77)
Dalbavancin	0.015	0.03	100.0e	100.0e	100.0e
Daptomycin	≤ 0.06	0.25	100.0	100.0	100.0
Vancomycin	0.5	0.5	100.0	100.0	100.0
Linezolid	1	2	100.0	100.0	100.0
Ceftriaxone	0.03	0.06	100.0	100.0	100.0
Ceftaroline	≤ 0.008	0.015	100.0	100.0	100.0
Penicillin	0.015	0.06	100.0	100.0	100.0
Clindamycin	≤ 0.25	> 2	79.8	87.7	85.7
Levofloxacin	0.5	1	98.1	97.4	98.7
Tetracycline	> 4	> 4	41.7	52.2	55.8
E. faecium (659)			(238)	(348)	(73)
Dalbavancin	0.06	> 2	[38.7]c	[81.9]c	[74.0]c
Daptomycin	1	2	[96.2]f	[100.0]f	[100.0]f
Vancomycin	0.5	> 16	36.6	76.1	61.6
Teicoplanin	1	> 16	39.9	82.2	67.1
Linezolid	1	2	99.2	99.7	100.0
Ampicillin	> 16	> 16	18.5	12.6	2.7
Levofloxacin	> 4	> 4	14.7	10.1	2.7

^aMIC₅₀ and MIC₉₀ values for the US, W-EU, and E-EU collection combined

^bTrimethoprim-sulfamethoxazole

^cThese breakpoints have been applied to all E. faecalis and E. faecium but are only approved for vancomycin-susceptible E. faecalis

^dThe percentage inhibited at ≤ 0.25 mg/L, the susceptible breakpoint for S. aureus published by US FDA and CLSI

^eThese breakpoints have been applied to all Streptococcus spp. other than S. pneumoniae, but are only approved for S. pyogenes, S. agalactiae, and S. dysgalactiae group

^fThe value in the brackets indicates percentage susceptible dose-dependent (SDD)

Vancomycin susceptibility varied from 97.3% (E-EU) to 98.3% (W-EU) among E. faecalis (97.5% in US; Table 2), and dalbavancin was highly active against vancomycin-susceptible E. faecalis (MIC_50/90, 0.03/0.06 mg/L; 100.0% susceptible [S] per US FDA and CLSI [98.5% inhibited at ≤ 0.12 mg/L]; Table 1). Dalbavancin coverage against E. faecalis per US FDA and CLSI criteria (97.9–98.7%S) was identical to teicoplanin (97.9–98.7%S) and comparable to daptomycin (99.2–100.0%S), vancomycin (97.3–98.3%S), and linezolid (97.3–99.8%S); however, based on MIC₅₀ values, dalbavancin was 16- to 32-fold more potent than those compounds (Table 2). All E. faecalis isolates were ampicillin susceptible (MIC_50/90, 1/1 mg/L; Table 2).

S. epidermidis was the third most common organism overall but ranked fourth in the US and W-EU and sixth in E-EU (Fig. 1). Oxacillin resistance rates among S. epidermidis were 66.9% in W-EU, 73.2% in US, and 86.5% in E-EU, and all isolates were inhibited at ≤ 0.25 mg/L of dalbavancin (MIC_50/90, 0.03/0.06 mg/L; 99.9% inhibited at ≤ 0.12 mg/L; Tables 1 and 2). Daptomycin (MIC_50/90, 0.25/0.5 mg/L) and vancomycin (MIC_50/90, 2/2 mg/L) were active against all S. epidermidis, whereas susceptibility to teicoplanin (US FDA and CLSI criteria) ranged from 97.3% (E-EU) to 99.2% (US) and 99.4% (W-EU) and susceptibility to linezolid ranged from 93.9% (US) to 96.4% (W-EU; Table 2).

BHS exhibited low dalbavancin MIC values (MIC_50/90, 0.015/0.03 mg/L) and high susceptibility rates for most comparator agents tested (Tables 1 and 2). E. faecium ranked third in W-EU, fifth in E-EU, and sixth in the US, and showed vancomycin susceptibility rates of 76.1% in W-EU, 61.6% in E-EU, and only 36.6% in the US (Table 2). Dalbavancin inhibited 100.0% of vancomycin-susceptible E. faecium at ≤ 0.25 mg/L (98.5% inhibited at ≤ 0.12 mg/L) but exhibited very limited activity against vancomycin-resistant E. faecium (Table 1). Linezolid was the most active compound tested against E. faecium (MIC_50/90, 1/2 mg/L; 99.5%S per US FDA and CLSI and 99.8%S per EUCAST; Table 2).

Discussion

Dalbavancin is a long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives [5, 7]. Although dalbavancin has not been evaluated in clinical trials for BSI and it is currently approved only for the treatment of ABSSSI, dalbavancin has shown clinical efficacy and good tolerability for various infections. Some observational studies and real-world clinical experiences suggest the efficacy of dalbavancin for infections needing long-term treatment courses, including osteomyelitis, prosthetic joint infection, and endocarditis. In these studies, dalbavancin was used as either first-line agent or, more commonly, as consolidation to complete the treatment course and allow for an early discharge [9, 13, 14].

Data from the dalbavancin clinical trials, where all patients had blood cultures obtained at baseline, indicated that a total of 40 ABSSSI patients who received dalbavancin had bacteremia at baseline caused by one or more of the following organisms: 26 S. aureus (21 MSSA and 5 MRSA), 6 S. agalactiae, 7 S. pyogenes, 2 S. anginosus group, and 1 E. faecalis. Thirty-four of 40 (85.0%) patients who received dalbavancin showed favorable clinical responses at 48 to 72 h and 32/40 (80.0%) were clinical successes at days 26 to 30 [6, 15]. Moreover, the efficacy and safety of dalbavancin for the treatment of BSI and cardiovascular infections have been evaluated in many observational studies and case reports [9, 14, 16–20].

Gatti et al. recently summarized the results of 144 patients affected by BSI or vascular infection that were treated with dalbavancin. Different dalbavancin dosage treatment durations were administered. Clinical success was obtained in 81.3% of cases and relapse was reported in 3.5% of cases [9]. In a case of prosthetic graft infection due to E. faecium, dalbavancin was successfully administered as a long-term suppressive therapy for a total of 62 weeks [13]. In the DALBACEN cohort study, 49 patients affected by BSI that received at least one dose of dalbavancin were assessed. Dalbavancin was administered as a single dose of 1000–1500 mg, or 1000 mg followed by 500 mg at day 8. Clinical success was documented in 100.0% of patients at 90 days (including two cases of BSI caused by E. faecium), with no case of relapse or resistance development [18].

In the present investigation, dalbavancin demonstrated potent in vitro and broad-spectrum activity against Gram-positive organisms isolated from patients with BSI in European and US medical centers, with MIC₉₀ values of 0.03 mg/L for S. aureus, BHS, and VGS; 0.06 mg/L for E. faecalis and S. epidermidis; and 0.12 mg/L for vancomycin-susceptible E. faecium. All organisms, except vancomycin-resistant enterococci and 1 S. haemolyticus isolate, were inhibited at the dalbavancin-susceptible breakpoint of ≤ 0.25 mg/L (US FDA and CLSI criteria). Additionally, dalbavancin MIC values were 8- to 16-fold lower than those of daptomycin and 32-fold lower than those of vancomycin when tested against S. aureus. These results are consistent with in vitro surveillance studies reported since 2002 and cited in several recent reviews. Additionally, these results indicate that resistance to other antimicrobial classes, with the exception of the VanA vancomycin-resistance phenotype, does not adversely affect dalbavancin activity [4, 8, 21, 22]. These results support further investigations to determine the role of dalbavancin in the treatment of BSI.

Author contribution

Helio Sader performed conceptualization, formal Analysis, funding acquisition, investigation, methodology, resources, supervision, visualization, writing – original draft, and writing – review and editing. Mariana Castanheira provided conceptualization, data curation, funding acquisition, investigation, methodology, resources, software, supervision, validation, and writing – review and editing. Michael Huband contributed formal analysis, methodology, software, validation, writing – review and editing. Dee Shortridge performed data curation, methodology, software, supervision, validation, visualization, and writing – review and editing. Cecilia Carvalhaes provided data curation, formal analysis, investigation, methodology, project administration, supervision, validation, and writing – review and editing. Rodrigo Mendes contributed conceptualization, data curation, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, writing – original draft, writing – review and editing.

Funding

This study was supported by Allergan (prior to its acquisition by AbbVie). Allergan (now AbbVie) was involved in the design and decision to present these results and JMI Laboratories received compensation fees for services in relation to preparing the manuscript. Allergan (now AbbVie) had no involvement in the collection, analysis, and interpretation of data.

Data availability

My manuscript has associated data in a data repository, including all data for which depositation is mandatory.

Code availability

Not applicable.

Declarations

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

The content has been read and approved by all co-authors and the manuscript has not been submitted elsewhere. Furthermore, all authors agree to transfer the copyright, following the policies of the journal at the time of acceptance/publication.

Conflict of interest

JMI Laboratories has no conflicts of interest to declare.

JMI Laboratories contracted to perform services in 2018–2020 for Achaogen, Inc., Affinity Biosensors, Albany College of Pharmacy and Health Sciences, Allecra Therapeutics, Allergan, Amicrobe Advanced Biomaterials, Inc., American Proficiency Institute, AmpliPhi Biosciences Corp., Amplyx Pharma, Antabio, Arietis Corp., Arixa Pharmaceuticals, Inc., Artugen Therapeutics USA, Inc., Astellas Pharma Inc., Athelas, Becton, Basilea Pharmaceutica Ltd., Bayer AG, Becton, Beth Israel Deaconess Medical Center, BIDMC, bioMerieux, Inc., bioMerieux SA, BioVersys Ag, Boston Pharmaceuticals, Bugworks Research Inc., CEM-102 Pharmaceuticals, Cepheid, Cidara Therapeutics, Inc., Cipla, Contrafect, Cormedix Inc., Crestone, Inc., Curza, CXC7, DePuy Synthes, Destiny Pharma, Dickinson and Company, Discuva Ltd., Dr. Falk Pharma GmbH, Emery Pharma, Entasis Therapeutics, Eurofarma Laboratorios SA, Fedora Pharmaceutical, F. Hoffmann-La Roche Ltd., Fimbrion Therapeutics, US Food and Drug Administration, Fox Chase Chemical Diversity Center, Inc., Gateway Pharmaceutical LLC, GenePOC Inc., Geom Therapeutics, Inc., GlaxoSmithKline plc, Guardian Therapeutics, Hardy Diagnostics, Harvard University, Helperby, HiMedia Laboratories, ICON plc, Idorsia Pharmaceuticals Ltd., IHMA, Iterum Therapeutics plc, Janssen Research & Development, Johnson & Johnson, Kaleido Biosciences, KBP Biosciences, Laboratory Specialists, Inc., Luminex, Matrivax, Mayo Clinic, Medpace, Meiji Seika Pharma Co., Ltd., Melinta Therapeutics, Inc., Menarini, Merck & Co., Inc., Meridian Bioscience Inc., Micromyx, Microchem Laboratory, MicuRx Pharmaceutics, Inc., Mutabilis Co., N8 Medical, Nabriva Therapeutics plc, National Institutes of Health, NAEJA-RGM, National University of Singapore, North Bristol NHS Trust, Novartis AG, Novome Biotechnologies, Oxoid Ltd., Paratek Pharmaceuticals, Inc., Pfizer, Inc., Pharmaceutical Product Development, LLC, Polyphor Ltd., Prokaryotics Inc., QPEX Biopharma, Inc., Ra Pharmaceuticals, Inc., Rhode Island Hospital, RIHML, Roche, Roivant Sciences, Ltd., Safeguard Biosystems, Salvat, Scynexis, Inc., SeLux Diagnostics, Inc., Shionogi and Co., Ltd., SinSa Labs, Specific Diagnostics, Spero Therapeutics, Summit Pharmaceuticals International Corp., SuperTrans Medical LT, Synlogic, T2 Biosystems, Taisho Pharmaceutical Co., Ltd., TenNor Therapeutics Ltd., Tetraphase Pharmaceuticals, The Medicines Company, The University of Queensland, Theravance Biopharma, Thermo Fisher Scientific, Tufts Medical Center, Universite de Sherbrooke, University of Colorado, University of Southern California-San Diego, University of Iowa, University of Iowa Hospitals and Clinics, University of North Texas Health Science Center, University of Wisconsin, UNT System College of Pharmacy, URMC, UT Southwestern, VenatoRx, Viosera Therapeutics, Vyome Therapeutics Inc., Wayne State University, Wockhardt, Yukon Pharmaceuticals, Inc., Zai Lab, and Zavante Therapeutics, Inc. There are no speakers’ bureaus or stock options to declare.